Missouri hearing considers bill to require insurers to cover nonopioid options for patients at elevated opioid risk

Representative Melanie Stitt told the House Insurance Committee that House Bill 804 would require insurers to honor a physician-patient decision to use nonopioid pain treatments when a patient is at elevated risk for opioid misuse. "If a patient is at an elevated risk for opioid use, then the insurer cannot deny the non opioid in favor of an opioid. They can't force the patient to try an opioid first, and they can't require higher cost sharing for the non opioid over an opioid," Stitt said.

The bill defines "elevated risk" as meeting one or more criteria listed in the measure: a current or prior diagnosis of a substance use disorder (not limited to opioids); a completed advanced health-care directive stating a preference to avoid opioids; increased risk for overdose or adverse effects based on age or diagnosis; or current prescription medicines that create contraindications with opioids. Stitt said the measure is intended to protect patients whose life experiences or medical conditions put them at higher risk of addiction or harm.

Supporters testified that the bill would expand nonopioid treatment access. A health-sector witness representing several providers and community groups said innovation has produced alternatives that can treat acute pain without opioids and that insurers should make those options available when clinically appropriate. Shannon Cooper, representing America's Health Insurance Plans, and Hampton Williams, general counsel for the Missouri Insurance Coalition, testified in opposition, warning the bill could limit insurers' ability to use prior authorization and could raise costs for plans and members. "That takes away all control an insurance company has to look at the medications you're prescribed and interact with your physician and say yes or no, we're not going to sell you this drug," Cooper said. Williams emphasized concerns about cost and the absence of generics for potential new nonopioid products: "Our concern is that this does not give us or give the insurers the ability to consider generic alternatives."

Committee members pressed both sides on prior authorization timelines and cost. Several lawmakers said they supported measures to reduce opioid harm but asked for guardrails so that expensive brand-name therapies would not automatically become mandatory without consideration of cost, clinical evidence and existing prior-authorization safeguards. A committee member noted Missouri's statutory timelines for prior authorization are comparatively short; insurers said those timelines help, but they urged explicit statutory language allowing them to consider treatment history and other clinical evidence.

Individuals speaking in opposition included a chronic pain patient, Mary Kramer, who described losing function when medications were restricted: "If I was not on opioids, I would not be able to work. I would be bed bound. And I would be contemplating ending my life." Kramer and others urged caution about policies that could increase barriers to pain control for patients who rely on long-term opioid therapy.

The committee took testimony from multiple stakeholders—physicians, insurers' trade groups, patient advocates and providers—and asked for additional information about available nonopioid treatment options, expected costs, and how the bill's language would affect prior-authorization processes. The hearing concluded with no recorded committee vote on HB 804; members signaled interest in possible amendments to address insurers' cost and prior-authorization concerns while preserving access for patients at documented elevated risk.

Ending: The committee hearing on House Bill 804 closed with staff and members noting follow-up work would likely be needed; no formal action was recorded at the hearing.